| 产品描述: | Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization. |
| 靶点: |
hCB2-R:2.81 nM (EC50) |
| 体外研究: |
Vicasinabin (0.03-3 mg/kg;静脉注射;单次) 在 LPS 诱发的葡萄膜炎小鼠模型中可使白细胞粘附率降低21%-82%,血管通透性降低102%-106%[2]。 Vicasinabin (10 mg/kg;口服;5 周) 在 STZ 诱发的糖尿病大鼠中可使视网膜血管通透性降低 73%[2]。 Vicasinabin (0.01-10 mg/kg;口服;治疗在激光损伤前 1 天开始,并持续每天服用直至第 7 天) 在激光诱发的 CNV 大鼠中可减少病变面积,ED50 为 0.32 mg/kg,并抑制小胶质细胞迁移[2]。 |
| 体内研究: |
Vicasinabin 在 CHO 细胞中是重组人和小鼠 CB2R 的完全激动剂 (EC50 分别为 2.81 nM 和 2.60 nM),对人类 CB1R 没有影响。 |
| 参考文献: |
1. Jean-Michel Adam, et al. Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives. Patent US20130116236A1. 2. Grether U, et al. RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. Front Pharmacol. 2024 Jul 12;15:1426446. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.79 ml |
13.951 ml |
27.902 ml |
| 5 mM |
0.558 ml |
2.79 ml |
5.58 ml |
| 10 mM |
0.279 ml |
1.395 ml |
2.79 ml |
| 50 mM |
0.056 ml |
0.279 ml |
0.558 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |